Ticker LaunchIPO · BCEL
Atreca, Inc.
Atreca, Inc. (BCEL) priced its initial public offering on Jun 20, 2019 at $17.00 per share, within its $16.00–$18.00 range, raising $125M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $455.3M. Cooley advised the company and Davis Polk advised the underwriters.
Atreca, Inc. is a biopharmaceutical company developing antibody-based immunotherapeutics for solid tumors. Its platform draws on patients with an active immune response against their tumors to identify antibody-target pairs, rather than starting from known targets.
- Status
- IPO
- Ticker
- BCEL
- Exchange
- Nasdaq Global Select
- Priced
- Jun 20, 2019
- IPO price
- $17.00
- Price range
- $16.00–$18.00
- Raised
- $125M
- Market cap at IPO price
- $455.3M
- First filed
- May 24, 2019
- Company counsel
- Cooley
- Underwriters' counsel
- Davis Polk
- Sector
- Biotech & pharma
- Country / state
- CA
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
- Analyst notes on the filing
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed May 24, 2019
- Latest amendment Jun 10, 2019
- Final prospectus (424B4) Jun 20, 2019
- All filings on EDGAR CIK 1532346
Other Biotech & pharma IPOs in 2019
- BridgeBio Pharma, Inc.BBIO · Jun 28, 2019 · $348.5M
- Adaptive Biotechnologies CorpADPT · Jun 27, 2019 · $300M
- Morphic Holding, Inc.MORF · Jun 27, 2019 · $90M
- Akero Therapeutics, Inc.AKRO · Jun 20, 2019 · $92M
- Prevail Therapeutics Inc.PRVL · Jun 20, 2019 · $125M
- Stoke Therapeutics, Inc.STOK · Jun 19, 2019 · $142M